Elosulfase alfa (Vimizim®)

Assessment Status Assessment process complete
Drug Elosulfase alfa
Brand Vimzim®
Indication For the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages.
Assessment Process
Rapid review commissioned 30/03/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 04/04/2016
NCPE assessment completed 08/12/2016
NCPE assessment outcome Reimbursement Not Recommended. The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations: May 2018